Randomisation of Relapsed and Refractory High-Risk Neuroblastoma Patients Treated with Long-Term Infusion of Anti-GD2 Antibody Dinutuximab Beta with or Without Subcutaneous Interleukin-2, A SIOPEN Study

被引：0

作者：

Lode, H. ^{[1
]}

Valteau-Couanet, D. ^{[2
]}

Gray, J. ^{[3
]}

Luksch, R. ^{[4
]}

Wieczorek, A. ^{[5
]}

Castel, V. ^{[6
]}

Ash, S. ^{[7
]}

Owens, C. ^{[8
]}

Laureys, G. ^{[9
]}

Papadakis, V. ^{[10
]}

Garaventa, A. ^{[11
]}

Manzitti, C. ^{[11
]}

Siebert, N. ^{[1
]}

Troschke-Meurer, S. ^{[1
]}

Glogova, E. ^{[12
]}

Poetschger, U. ^{[12
]}

Ladenstein, R. ^{[12
]}

机构：

[1] Univ Med Greifswald, Pediat Hematol & Oncol, Greifswald, Germany

[2] Paris Sud Univ, Gustave Roussy, Children & Adolescent Oncol Dept, Paris, France

[3] Univ Southampton, Pediat Oncol, Southampton, Hants, England

[4] Fdn IRCCS Ist Nazl Tumori, Pediat Oncol, Milan, Italy

[5] Jagiellonian Univ, Coll Med, Pediat Hematol Oncol, Krakow, Poland

[6] Hosp Univ & Politecn La Fe, Pediat Oncol, Valencia, Spain

[7] Tel Aviv Univ, Sackler Fac Med, Schneider Childrens Med Ctr Israel, Petah Tiqwa, Israel

[8] Our Ladys Childrens Hosp Crumlin, Pediat Haematol Oncol, Dublin, Ireland

[9] Univ Hosp Ghent, Pediat Oncol, Ghent, Belgium

[10] Agia Sofia Childrens Hosp, Dept Pediat Hematol Oncol, Athens, Greece

[11] IRCCS Ist Giannina Gaslini, Oncol Unit, Genoa, Italy

[12] St Anna Kinderkrebsforsch, CCRI, Vienna, Austria

来源：

PEDIATRIC BLOOD & CANCER | 2019年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

FP054 SIOP

引用

页码：S34 / S35

页数：2

共 50 条

[1] Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (sclL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial.
Lode, Holger N.
Valteau-Couanet, Dominique
Gray, Juliet
Luksch, Roberto
Wieczorek, Aleksandra
Castel, Victoria
Ash, Shifra
Laureys, Genevieve
Papadakis, Vassilios
Owens, Cormac
Garaventa, Alberto
Manzitti, Carla
Siebert, Nikolai
Troschke-Meurer, Sascha
Glogova, Evgenia
Poetschger, Ulrike
Ladenstein, Ruth Lydia
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[2] SINGLE AGENT ACTIVITY OF THE ANTI-GD2 ANTIBODY DINUTUXIMAB BETA LONG-TERM INFUSION IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH RELAPSED AND REFRACTORY DISEASE. A MULTICENTER PHASE II TRIAL
Lode, Holger
Ehlert, Karoline
Huber, Stephanie
Siebert, Nikolai
Troschke-Meurer, Sascha
Zumpe, Maxi
Loibner, Hans
Ladenstein, Ruth
PEDIATRIC BLOOD & CANCER, 2022, 69
[3] Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma
Ploessl, Cady
Pan, Alice
Maples, Kathryn T.
Lowe, Denise K.
ANNALS OF PHARMACOTHERAPY, 2016, 50 (05) : 416 - 422
[4] Long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) activity and efficacy in high-risk relapsed/refractory neuroblastoma patients.
Lode, Holger N.
Valteau-Couanet, Dominique
Garaventa, Alberto
Gray, Juliet
Castel, Victoria
Yaniv, Isaac
Siebert, Nikolai
Jensen, Christian
Endres, Stefanie
Pill, Lena
Eger, Christin
Seidel, Diana
Juettner, Madlen
Kietz, Silke
Ehlert, Karoline
Janzek, Evelyne
Loibner, Hans
Mueller, Ina
Ladenstein, Ruth L.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[5] Single-agent activity of the anti-GD2 antibody dinutuximab beta given as a long-term infusion in relapsed and refractory neuroblastoma (APN311-304)
Lode, Holger N.
Ehlert, Karoline
Huber, Stephanie
Siebert, Nikolai
Troschke-Meurer, Sascha
Zumpe, Maxi
Loibner, Hans
Ladenstein, Ruth Lydia
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.
Ladenstein, Ruth Lydia
Poetschger, Ulrike
Valteau-Couanet, Dominique
Gray, Juliet
Luksch, Roberto
Balwierz, Walentyna
Castel, Victoria
Ash, Shifra
Popovic, Maja Beck
Laureys, Genevieve
Chan, Godfrey Chi Fung
Ruud, Ellen
Vettenranta, Kim
Owens, Cormac
Schroeder, Henrik
Loibner, Hans
Ambros, Peter F.
Sarnacki, Sabine
Boterberg, Tom
Lode, Holger N.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[7] Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma
Ceylan, Kiraz
Jahns, Luciana J.
Lode, Bjoern N.
Ehlert, Karoline
Kietz, Silke
Troschke-Meurer, Sascha
Siebert, Nikolai
Lode, Holger N.
PEDIATRIC BLOOD & CANCER, 2018, 65 (06)
[8] Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO
Mueller, Ina
Ehlert, Karoline
Endres, Stefanie
Pill, Lena
Siebert, Nikolai
Kietz, Silke
Brock, Penelope
Garaventa, Alberto
Valteau-Couanet, Dominique
Janzek, Evelyne
Hosten, Norbert
Zinke, Andreas
Barthlen, Winfried
Varol, Emine
Loibner, Hans
Ladenstein, Ruth
Lode, Holger N.
MABS, 2018, 10 (01) : 55 - 61
[9] Immune activation and clinical responses following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in high-risk neuroblastoma patients.
Lode, Holger N.
Jensen, Christian
Endres, Stefanie
Pill, Lena
Siebert, Nikolai
Kietz, Silke
Ehlert, Karoline
Brock, Penelope
Valteau-Couanet, Dominique
Janzek, Evelyne
Loibner, Hans
Ladenstein, Ruth L.
Mueller, Ina
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[10] Immune activation, clinical response and survival following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in high-risk neuroblastoma patients
Lode, Holger
Jensen, Christian
Siebert, Nikolai
Kietz, Silke
Ehlert, Karoline
Mueller, Ina
Ladenstein, Ruth
Janzek, Evelyne
Loibner, Hans
CANCER RESEARCH, 2014, 74 (19)

← 1 2 3 4 5 →